Simply Wall St Keeps Bachem Fair Value at CHF 110 as Stock Rises

Bachem Holding AG (ISIN CH1176493729, ticker BANB) saw its stock rise 3.32% on October 6, 2026, closing at EUR 88.08 on the Lang & Schwarz exchange. Simply Wall St reaffirmed its CHF 110.00 fair value estimate for the biotechnology company, emphasizing the importance of capacity execution and customer demand in its valuation.

The firm adjusted its revenue growth assumption upward from 32.40% to 34.38% while increasing the discount rate from 4.57% to 4.80%. Despite these changes, the fair value remained unchanged at CHF 110.00, highlighting the need for Bachem to translate its planned capacity into actual revenue.

In its first-half 2026 earnings report, Bachem reported sales of CHF 326.40 million, a 4.30% increase from the same period in 2025. Local-currency growth was higher at 7.30%, indicating the impact of currency fluctuations. EBITDA reached CHF 82.80 million with a margin of 25.40%, and management maintained its outlook for 35.00% to 40.00% sales growth in local currencies for 2026.

Analysts remain divided on Bachem's prospects. Investing.com's average 12-month target is CHF 84.30, with opinions ranging from Buy to Hold to Sell. JPMorgan set a target of CHF 90.00, while Barclays raised its target to CHF 80.00 from CHF 70.00, reflecting differing views on the company's expansion pace.